PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2016-01-01
- Employees
- -
- Market Cap
- -
- Website
- https://www.parkerici.org/
Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- Drug: NKTR-214 (Cohort A)Drug: CDX-301 (Cohort B and C)Radiation: Stereotactic body radiation therapy (SBRT) (Cohort B)Drug: INO-5151 (Cohort C)Device: Cellectra 2000
- First Posted Date
- 2019-02-08
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Parker Institute for Cancer Immunotherapy
- Target Recruit Count
- 43
- Registration Number
- NCT03835533
- Locations
- 🇺🇸
Angeles Clinic, Los Angeles, California, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
🇺🇸Mount Sinai, New York, New York, United States
Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention
- Conditions
- Metastatic Melanoma
- Interventions
- Drug: Placebo for antibioticDrug: Matching Placebo for SER-401
- First Posted Date
- 2019-01-25
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Parker Institute for Cancer Immunotherapy
- Target Recruit Count
- 14
- Registration Number
- NCT03817125
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer
- Conditions
- Advanced Metastatic CancerAdvanced Prostate Cancer
- First Posted Date
- 2018-08-29
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Parker Institute for Cancer Immunotherapy
- Target Recruit Count
- 100
- Registration Number
- NCT03651271
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸Stanford University, Palo Alto, California, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma
- Conditions
- Metastatic Pancreatic Adenocarcinoma
- Interventions
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2022-12-23
- Lead Sponsor
- Parker Institute for Cancer Immunotherapy
- Target Recruit Count
- 129
- Registration Number
- NCT03214250
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸Stanford University, Stanford, California, United States
Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy
- First Posted Date
- 2016-04-07
- Last Posted Date
- 2022-12-23
- Lead Sponsor
- Parker Institute for Cancer Immunotherapy
- Target Recruit Count
- 20
- Registration Number
- NCT02731729
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
News
Dr. Elizabeth Mittendorf Outlines Vision as ASCO President-Elect to Advance Multidisciplinary Cancer Care and Workforce Support
Dr. Elizabeth Mittendorf, the 2026-2027 ASCO President-Elect, will focus on advancing multidisciplinary collaboration, broadening clinical trial access, and strengthening oncology workforce support during her presidency.
Lumanity and Parker Institute Form Strategic Alliance to Accelerate Cancer Immunotherapy Development
Lumanity and the Parker Institute for Cancer Immunotherapy have announced a strategic alliance to accelerate the development and delivery of next-generation cancer immunotherapies.
Nomic and PICI Partner to Profile Protein Biomarkers in Immunotherapy Response Study
Nomic Bio and the Parker Institute for Cancer Immunotherapy (PICI) are collaborating to identify protein biomarkers linked to immunotherapy responses across various cancers.
BostonGene Sweeps 2024 Pharmaceutical Excellence Awards with AI-Powered Cancer Diagnostics Platform
• BostonGene has secured five prestigious awards in the 2024 Pharmaceutical Excellence Awards, recognizing their innovative AI-powered platform for cancer diagnostics and treatment optimization. • The company's breakthrough Tumor Microenvironment Typing technology offers a comprehensive biomarker system for predicting immunotherapy response and prognosis across multiple cancer types. • BostonGene's AI-based digital pathology platform revolutionizes cancer diagnostics by automating tissue analysis and eliminating human variability in biomarker detection.
Nomic and PICI Partner to Profile Immunotherapy Responses in RADIOHEAD Study
Nomic Bio and the Parker Institute for Cancer Immunotherapy (PICI) are collaborating to analyze protein biomarkers in immunotherapy patients.